Immunomedics (IMMU) 3.33 $IMMU
Immunomedics Announces Third Quarter Fiscal 2014 Results and Clinical Program Developments
GlobeNewswire - Wed May 07, 3:47PM CDT
Immunomedics, Inc., (Nasdaq:IMMU) today reported financial results for the third quarter ended March 31, 2014. The Company also highlighted recent key developments and planned activities for its clinical pipeline.
Immunomedics Closes $30 Million Public Offering of Common Stock
GlobeNewswire - Wed May 07, 3:47PM CDT
Immunomedics, Inc., (Nasdaq:IMMU) today announced that it has closed its recently announced underwritten public offering of nine million shares of its common stock. The gross proceeds from this offering to Immunomedics are expected to be $30.15 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Immunomedics. Immunomedics has granted the underwriters a 30-day option to purchase up to an additional 1.35 million shares of common stock. All of the shares sold in the offering were sold by Immunomedics, with the proceeds to fund the Company's Phase III clinical trial for patients with advanced pancreatic cancer and its ongoing Phase II expansion trials for IMMU-132 and IMMU-130, as well as for working capital and general corporate purposes.
Market Updates on Active Equities -- Research on Fifth Third Bancorp., Immunomedics, Gerdau, and HD Supply Holdings
PR Newswire - Mon May 05, 11:22AM CDT
The trading session on Friday, May 02, 2014 ended lower on a note as the Dow Jones Industrial Average finished at 16,512.89, down 0.28% and the NASDAQ Composite closed at 4,123.90, down 0.09%. The S&P 500 finished the day 0.13% lower at 1,881.14. During the trading session, six out of ten sectors finished on a lower note. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Fifth Third Bancorp. (NASDAQ: FITB), Immunomedics Inc. (NASDAQ: IMMU), Gerdau S.A. (NYSE: GGB) and HD Supply Holdings Inc. (NASDAQ: HDS). Free technical research on FITB, IMMU, GGB and HDS can be downloaded upon signing up at:
Immunomedics Announces Conference Call and Webcast for Third Quarter Fiscal 2014 Financial Results
GlobeNewswire - Mon May 05, 8:42AM CDT
Immunomedics, Inc., (Nasdaq:IMMU) today announced that it will host a conference call and live audio webcast on Thursday, May 8, 2014 at 10:00 a.m. Eastern Time to discuss financial results for the third quarter of fiscal year 2014, and review key clinical developments and future planned activities.
Immunomedics expects USD30m from public offering of common stock
M2 - Mon May 05, 7:57AM CDT
Biopharmaceutical company Immunomedics (NasdaqGM:IMMU) said on Friday that it has priced its public offering of 9 million shares of its common stock.
Investors look to Lighten Up on Shares of Immunomedics, Shares Down 21.7% (IMMU)
Comtex SmarTrend(R) - Fri May 02, 10:10AM CDT
Immunomedics (NASDAQ:IMMU) is one of today's worst performing low-priced stocks, down 21.7% to $3.24 on 4.7x average daily volume. Immunomedics has traded 3.4 million shares thus far today, vs. average volume of 722,000 shares per day. The stock has underperformed the Dow (-21.7% to the Dow's -0.2%) and underperformed the S&P 500 (-21.7% to the S&P's -0.1%) during today's trading.
Immunomedics Prices $30 Million Public Offering of Common Stock
GlobeNewswire - Fri May 02, 8:20AM CDT
Immunomedics, Inc., (Nasdaq:IMMU) today announced the pricing of an underwritten public offering of 9 million shares of its common stock, offered at a price to the public of $3.35 per share. The gross proceeds from this offering to Immunomedics are expected to be $30.15 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Immunomedics. Immunomedics has granted the underwriters a 30-day option to purchase up to an additional 1.35 million shares of common stock. The offering is expected to close on or about May 7, 2014, subject to customary closing conditions. All of the shares sold in the offering are being sold by Immunomedics, with the proceeds to fund the Company's Phase III clinical trial for patients with advanced pancreatic cancer and its ongoing Phase II expansion trials for IMMU-132 and IMMU-130, as well as for working capital and general corporate purposes.
Global Metastatic Hepatocellular Carcinoma (HCC) Clinical Trials Review 2014
M2 - Fri May 02, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z7xx64/metastatic) has announced the addition of the "Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Hepatocellular Carcinoma (HCC) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Hepatocellular Carcinoma (HCC). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Hepatocellular Carcinoma (HCC). Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Pfizer Inc. - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Bayer AG - Novartis AG - MolMed S.p.A. - Immunomedics, Inc. - Eli Lilly and Company - Affitech A/S - Adherex Technologies Inc. - National Cancer Institute - UNC Lineberger Comprehensive Cancer Center - North Central Cancer Treatment Group - Far Eastern Memorial Hospital - Thomas Jefferson University - Leiden University Medical Center - The University of Hong Kong - University of Florida For more information visit http://www.researchandmarkets.com/research/z7xx64/metastatic
Immunomedics Announces Proposed Public Offering of Common Stock
GlobeNewswire - Thu May 01, 3:01PM CDT
Immunomedics, Inc., (Nasdaq:IMMU) today announced that it is offering to sell, subject to market and other conditions, shares of its common stock pursuant to an effective shelf registration statement. In connection with this offering, Immunomedics intends to grant the underwriters a 30-day option to purchase additional shares of common stock. All of the shares to be sold in the offering are being sold by Immunomedics, with the proceeds to fund the Company's Phase III clinical trial for patients with advanced pancreatic cancer and its ongoing Phase II expansion trials for IMMU-132 and IMMU-130, as well as for working capital and general corporate purposes. Wells Fargo Securities, LLC and Jefferies LLC are acting as joint book-running managers.
UPCOMING DEADLINE: Levi & Korsinsky, LLP Announces Class Action Involving IMMUNOMEDICS, INC. and Its Board of Directors and a Deadline of April 28, 2014 to Seek a Lead Plaintiff Position -- IMMU
GlobeNewswire - Wed Apr 23, 6:11PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Immunomedics, Inc. ("Immunomedics" or the "Company"
(Nasdaq:IMMU) common stock between May 9, 2013 and October 9, 2013.
Immunomedics Highlights Clinical Pipeline for Solid Cancer and Lupus Therapy at R & D Day
GlobeNewswire - Wed Apr 23, 11:30AM CDT
Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced a historical milestone in the Company's listing at the NASDAQ stock market, which is going on 30 years strong. Only a small, elite group of biopharmaceutical companies has this longevity.
Immunomedics, Inc. [IMMU] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Tue Apr 22, 10:29AM CDT
What:
Global Metastatic Pancreatic Cancer Therapeutics Pipeline Review 2014 - Analysis of 27 Companies & 37 Drug Profiles
M2 - Tue Apr 22, 3:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gctlqw/metastatic) has announced the addition of the "Metastatic Pancreatic Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Pancreatic Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Adherex Technologies Inc. - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - FibroGen, Inc. - Novartis AG - Pfizer Inc. - Celgene Corporation - Bayer AG - Halozyme Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - Immunomedics, Inc. - Synta Pharmaceuticals Corp. - NanoCarrier Co., Ltd. - Rexahn Pharmaceuticals, Inc. - Insys Therapeutics, Inc. - OncoMed Pharmaceuticals, Inc. - Merrimack Pharmaceuticals, Inc. - Pharma Mar, S.A. - AB Science - Oncovir, Inc. - ParinGenix, Inc. - Regulon Inc. - Fountain Biopharma Inc. - Oncozyme Pharma Inc. - AbbVie Inc. Drug Profiles - paclitaxel albumin-bound - irinotecan sucrosofate liposomal - masitinib - cisplatin liposomal - cisplatin - refametinib - selumetinib sulfate - trametinib dimethyl sulfoxide - docetaxel - paclitaxel albumin-bound - ganetespib - RX-0201 - irinotecan sucrosofate liposomal - PGX-100 - lurbinectedin - yttrium Y 90 clivatuzumab tetraxetan - Cancer Inhibitor Macrobeads - TL-118 - LY-2090314 - hydroxychloroquine - LY-2495655 - PEGPH-20 - M-402 - pentamidine isethionate - veliparib - galunisertib - ADH-1 - FG-3019 - demcizumab - LCL-161 For more information visit http://www.researchandmarkets.com/research/gctlqw/metastatic
Biotech Investing 101: What Investors Need to Know About Phase 1 Trials
Catherine Shaffer, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
Clinical trials are huge milestones in drug development, and the success or failure of the whole company can hinge on the outcome of a single trial. The odds are generally against any given drug, as many more drugs fail in clinical trials than...
UPCOMING DEADLINE: Levi & Korsinsky, LLP Announces Class Action Involving IMMUNOMEDICS, INC. and Its Board of Directors and a Deadline of April 28, 2014 to Seek a Lead Plaintiff Position
Business Wire - Thu Apr 10, 11:05AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Immunomedics, Inc. ("Immunomedics" or the "Company" (Nasdaq: IMMU) common stock between May 9, 2013 and October 9, 2013.
Global B-Cell Non-Hodgkin Lymphoma Clinical Trials Review
M2 - Thu Apr 10, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6w5nm9/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014" report to their offering. B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the B-Cell Non-Hodgkin Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on B-Cell Non-Hodgkin Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating B-Cell Non-Hodgkin Lymphoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - F. Hoffmann-La Roche Ltd. - Celgene Corporation - Takeda Pharmaceutical Company Limited - GlaxoSmithKline plc - Amgen Inc. - Novartis AG - Pharmacyclics, Inc. - Pfizer Inc. - Biogen Idec Inc. - Immunomedics, Inc. Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Mayo Clinic - Southwest Oncology Group - Groupe d'Etudes de Lymphomes de L'Adulte - City of Hope National Medical Center - Stanford University For more information visit http://www.researchandmarkets.com/research/6w5nm9/bcell
Immunomedics to Ring Opening Bell and Host R&D Day at the NASDAQ Stock Market
GlobeNewswire - Thu Apr 10, 7:30AM CDT
Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that Dr. David M. Goldenberg, Founder and Chairman of the Board, and Cynthia L. Sullivan, President and Chief Executive Officer, will ring the Opening Bell at the NASDAQ MarketSite in Times Square, New York City, on Wednesday, April 23, 2014, in honor of the Company's 30-year uninterrupted listing on the NASDAQ Stock Market. Following the Opening Bell Ceremony, the Company will host a R&D day at the NASDAQ MarketSite.
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Immunomedics, Inc.
Business Wire - Tue Apr 08, 9:32AM CDT
Law Offices of Howard G. Smith reminds investors that all purchasers of the common stock of Immunomedics, Inc. ("Immunomedics" or the "Company" (NASDAQ:IMMU) between May 9, 2013 and October 9, 2013, inclusive (the "Class Period" , have until April 28, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
Immunomedics Reports Preclinical Results on SN-38 Antibody-Drug Conjugates as a Potential Novel Platform for Treating Cancer
GlobeNewswire - Tue Apr 08, 8:39AM CDT
/p>
Today’s Top Biotech Stories: Takeda, Eli Lilly, Immunomedics, and Pharmacyclics
Leo Sun, The Motley Fool - Motley Fool - Tue Apr 08, 8:21AM CDT
Let's take a look at four stocks -- Takeda , Eli Lilly , Immunomedics , and Pharmacyclics -- which could make waves in the health care sector this morning. Takeda and Eli Lilly ordered to pay $9 billion for Actos cancer risks ...
Immunomedics Announces Third Quarter Fiscal 2014 Results and Clinical Program Developments
GlobeNewswire - Wed May 07, 3:47PM CDT
Immunomedics, Inc., (Nasdaq:IMMU) today reported financial results for the third quarter ended March 31, 2014. The Company also highlighted recent key developments and planned activities for its clinical pipeline.
Immunomedics Closes $30 Million Public Offering of Common Stock
GlobeNewswire - Wed May 07, 3:47PM CDT
Immunomedics, Inc., (Nasdaq:IMMU) today announced that it has closed its recently announced underwritten public offering of nine million shares of its common stock. The gross proceeds from this offering to Immunomedics are expected to be $30.15 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Immunomedics. Immunomedics has granted the underwriters a 30-day option to purchase up to an additional 1.35 million shares of common stock. All of the shares sold in the offering were sold by Immunomedics, with the proceeds to fund the Company's Phase III clinical trial for patients with advanced pancreatic cancer and its ongoing Phase II expansion trials for IMMU-132 and IMMU-130, as well as for working capital and general corporate purposes.
Market Updates on Active Equities -- Research on Fifth Third Bancorp., Immunomedics, Gerdau, and HD Supply Holdings
PR Newswire - Mon May 05, 11:22AM CDT
The trading session on Friday, May 02, 2014 ended lower on a note as the Dow Jones Industrial Average finished at 16,512.89, down 0.28% and the NASDAQ Composite closed at 4,123.90, down 0.09%. The S&P 500 finished the day 0.13% lower at 1,881.14. During the trading session, six out of ten sectors finished on a lower note. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Fifth Third Bancorp. (NASDAQ: FITB), Immunomedics Inc. (NASDAQ: IMMU), Gerdau S.A. (NYSE: GGB) and HD Supply Holdings Inc. (NASDAQ: HDS). Free technical research on FITB, IMMU, GGB and HDS can be downloaded upon signing up at:
Immunomedics Announces Conference Call and Webcast for Third Quarter Fiscal 2014 Financial Results
GlobeNewswire - Mon May 05, 8:42AM CDT
Immunomedics, Inc., (Nasdaq:IMMU) today announced that it will host a conference call and live audio webcast on Thursday, May 8, 2014 at 10:00 a.m. Eastern Time to discuss financial results for the third quarter of fiscal year 2014, and review key clinical developments and future planned activities.
Immunomedics expects USD30m from public offering of common stock
M2 - Mon May 05, 7:57AM CDT
Biopharmaceutical company Immunomedics (NasdaqGM:IMMU) said on Friday that it has priced its public offering of 9 million shares of its common stock.
Investors look to Lighten Up on Shares of Immunomedics, Shares Down 21.7% (IMMU)
Comtex SmarTrend(R) - Fri May 02, 10:10AM CDT
Immunomedics (NASDAQ:IMMU) is one of today's worst performing low-priced stocks, down 21.7% to $3.24 on 4.7x average daily volume. Immunomedics has traded 3.4 million shares thus far today, vs. average volume of 722,000 shares per day. The stock has underperformed the Dow (-21.7% to the Dow's -0.2%) and underperformed the S&P 500 (-21.7% to the S&P's -0.1%) during today's trading.
Immunomedics Prices $30 Million Public Offering of Common Stock
GlobeNewswire - Fri May 02, 8:20AM CDT
Immunomedics, Inc., (Nasdaq:IMMU) today announced the pricing of an underwritten public offering of 9 million shares of its common stock, offered at a price to the public of $3.35 per share. The gross proceeds from this offering to Immunomedics are expected to be $30.15 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Immunomedics. Immunomedics has granted the underwriters a 30-day option to purchase up to an additional 1.35 million shares of common stock. The offering is expected to close on or about May 7, 2014, subject to customary closing conditions. All of the shares sold in the offering are being sold by Immunomedics, with the proceeds to fund the Company's Phase III clinical trial for patients with advanced pancreatic cancer and its ongoing Phase II expansion trials for IMMU-132 and IMMU-130, as well as for working capital and general corporate purposes.
Global Metastatic Hepatocellular Carcinoma (HCC) Clinical Trials Review 2014
M2 - Fri May 02, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z7xx64/metastatic) has announced the addition of the "Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Hepatocellular Carcinoma (HCC) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Hepatocellular Carcinoma (HCC). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Hepatocellular Carcinoma (HCC). Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Pfizer Inc. - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Bayer AG - Novartis AG - MolMed S.p.A. - Immunomedics, Inc. - Eli Lilly and Company - Affitech A/S - Adherex Technologies Inc. - National Cancer Institute - UNC Lineberger Comprehensive Cancer Center - North Central Cancer Treatment Group - Far Eastern Memorial Hospital - Thomas Jefferson University - Leiden University Medical Center - The University of Hong Kong - University of Florida For more information visit http://www.researchandmarkets.com/research/z7xx64/metastatic
Immunomedics Announces Proposed Public Offering of Common Stock
GlobeNewswire - Thu May 01, 3:01PM CDT
Immunomedics, Inc., (Nasdaq:IMMU) today announced that it is offering to sell, subject to market and other conditions, shares of its common stock pursuant to an effective shelf registration statement. In connection with this offering, Immunomedics intends to grant the underwriters a 30-day option to purchase additional shares of common stock. All of the shares to be sold in the offering are being sold by Immunomedics, with the proceeds to fund the Company's Phase III clinical trial for patients with advanced pancreatic cancer and its ongoing Phase II expansion trials for IMMU-132 and IMMU-130, as well as for working capital and general corporate purposes. Wells Fargo Securities, LLC and Jefferies LLC are acting as joint book-running managers.
UPCOMING DEADLINE: Levi & Korsinsky, LLP Announces Class Action Involving IMMUNOMEDICS, INC. and Its Board of Directors and a Deadline of April 28, 2014 to Seek a Lead Plaintiff Position -- IMMU
GlobeNewswire - Wed Apr 23, 6:11PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Immunomedics, Inc. ("Immunomedics" or the "Company"
(Nasdaq:IMMU) common stock between May 9, 2013 and October 9, 2013. Immunomedics Highlights Clinical Pipeline for Solid Cancer and Lupus Therapy at R & D Day
GlobeNewswire - Wed Apr 23, 11:30AM CDT
Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced a historical milestone in the Company's listing at the NASDAQ stock market, which is going on 30 years strong. Only a small, elite group of biopharmaceutical companies has this longevity.
Immunomedics, Inc. [IMMU] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Tue Apr 22, 10:29AM CDT
What:
Global Metastatic Pancreatic Cancer Therapeutics Pipeline Review 2014 - Analysis of 27 Companies & 37 Drug Profiles
M2 - Tue Apr 22, 3:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gctlqw/metastatic) has announced the addition of the "Metastatic Pancreatic Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Pancreatic Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Adherex Technologies Inc. - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - FibroGen, Inc. - Novartis AG - Pfizer Inc. - Celgene Corporation - Bayer AG - Halozyme Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - Immunomedics, Inc. - Synta Pharmaceuticals Corp. - NanoCarrier Co., Ltd. - Rexahn Pharmaceuticals, Inc. - Insys Therapeutics, Inc. - OncoMed Pharmaceuticals, Inc. - Merrimack Pharmaceuticals, Inc. - Pharma Mar, S.A. - AB Science - Oncovir, Inc. - ParinGenix, Inc. - Regulon Inc. - Fountain Biopharma Inc. - Oncozyme Pharma Inc. - AbbVie Inc. Drug Profiles - paclitaxel albumin-bound - irinotecan sucrosofate liposomal - masitinib - cisplatin liposomal - cisplatin - refametinib - selumetinib sulfate - trametinib dimethyl sulfoxide - docetaxel - paclitaxel albumin-bound - ganetespib - RX-0201 - irinotecan sucrosofate liposomal - PGX-100 - lurbinectedin - yttrium Y 90 clivatuzumab tetraxetan - Cancer Inhibitor Macrobeads - TL-118 - LY-2090314 - hydroxychloroquine - LY-2495655 - PEGPH-20 - M-402 - pentamidine isethionate - veliparib - galunisertib - ADH-1 - FG-3019 - demcizumab - LCL-161 For more information visit http://www.researchandmarkets.com/research/gctlqw/metastatic
Biotech Investing 101: What Investors Need to Know About Phase 1 Trials
Catherine Shaffer, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
Clinical trials are huge milestones in drug development, and the success or failure of the whole company can hinge on the outcome of a single trial. The odds are generally against any given drug, as many more drugs fail in clinical trials than...
UPCOMING DEADLINE: Levi & Korsinsky, LLP Announces Class Action Involving IMMUNOMEDICS, INC. and Its Board of Directors and a Deadline of April 28, 2014 to Seek a Lead Plaintiff Position
Business Wire - Thu Apr 10, 11:05AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Immunomedics, Inc. ("Immunomedics" or the "Company"
(Nasdaq: IMMU) common stock between May 9, 2013 and October 9, 2013. Global B-Cell Non-Hodgkin Lymphoma Clinical Trials Review
M2 - Thu Apr 10, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6w5nm9/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014" report to their offering. B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the B-Cell Non-Hodgkin Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on B-Cell Non-Hodgkin Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating B-Cell Non-Hodgkin Lymphoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - F. Hoffmann-La Roche Ltd. - Celgene Corporation - Takeda Pharmaceutical Company Limited - GlaxoSmithKline plc - Amgen Inc. - Novartis AG - Pharmacyclics, Inc. - Pfizer Inc. - Biogen Idec Inc. - Immunomedics, Inc. Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Mayo Clinic - Southwest Oncology Group - Groupe d'Etudes de Lymphomes de L'Adulte - City of Hope National Medical Center - Stanford University For more information visit http://www.researchandmarkets.com/research/6w5nm9/bcell
Immunomedics to Ring Opening Bell and Host R&D Day at the NASDAQ Stock Market
GlobeNewswire - Thu Apr 10, 7:30AM CDT
Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that Dr. David M. Goldenberg, Founder and Chairman of the Board, and Cynthia L. Sullivan, President and Chief Executive Officer, will ring the Opening Bell at the NASDAQ MarketSite in Times Square, New York City, on Wednesday, April 23, 2014, in honor of the Company's 30-year uninterrupted listing on the NASDAQ Stock Market. Following the Opening Bell Ceremony, the Company will host a R&D day at the NASDAQ MarketSite.
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Immunomedics, Inc.
Business Wire - Tue Apr 08, 9:32AM CDT
Law Offices of Howard G. Smith reminds investors that all purchasers of the common stock of Immunomedics, Inc. ("Immunomedics" or the "Company"
(NASDAQ:IMMU) between May 9, 2013 and October 9, 2013, inclusive (the "Class Period" , have until April 28, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit. Immunomedics Reports Preclinical Results on SN-38 Antibody-Drug Conjugates as a Potential Novel Platform for Treating Cancer
GlobeNewswire - Tue Apr 08, 8:39AM CDT
/p>
Today’s Top Biotech Stories: Takeda, Eli Lilly, Immunomedics, and Pharmacyclics
Leo Sun, The Motley Fool - Motley Fool - Tue Apr 08, 8:21AM CDT
Let's take a look at four stocks -- Takeda , Eli Lilly , Immunomedics , and Pharmacyclics -- which could make waves in the health care sector this morning. Takeda and Eli Lilly ordered to pay $9 billion for Actos cancer risks ...
